Stock Analiz

Strata Critical Medical, Inc. SRTA

Medical/Nursing Services · IPO 2019 · data as of November 13, 2026

$5.51Market cap $492M
Open the interactive analysis →

Strata Critical Medical, Inc. (SRTA) is a healthcare company listed in the US with a market value of about $492M. In the twelve months to September 30, 2026 it had revenue of $281M and net income of -$25M, a net margin of -8.8%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 610.6, a 5-year average ROIC of -13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.

About Strata Critical Medical

Strata Critical Medical is listed in the US and classified in medical/nursing services, IPO year 2019. Revenue went from $67M in 2021 to $197M in 2025, growth of about 30.9% a year. It was profitable in 2 of the last 7 years in our data. Its share count rose by 15% over three years (dilution for shareholders).

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E102.5
P/FCF610.6
P/S1.8
P/B1.8
EV/EBITDA138.5
PEG—
Dividend yield0.00%
FCF yield0.2%
Shareholder yield0.0%
Intrinsic value vs. price−84%

Growth and quality

Revenue growth (1 yr)34.3%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-19.2%
ROIC (5-yr avg.)-12.9%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$281M$197M$147M$225M$146M$67M——
Net income-$25M$41M-$27M-$56M-$27M-$37M-$21M$2M
Free cash flow$806000-$59M-$33M-$34M-$38M-$6M——
EPS (diluted)$-0.30$0.50$-0.35$-0.76$-0.38$0.01$-2.17$0.19
Net margin-8.8%21.0%-18.6%-24.9%-18.7%-55.0%——
ROIC—-7.9%-9.7%-25.7%-17.8%-3.6%-10.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $9.62, 75% above the current price; targets range from $8.00 to $13.00; the consensus rating is “Strong buy”; expected EPS is $-0.16 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Strata Critical Medical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Strata Critical Medical pay a dividend?

Not currently.

Is Strata Critical Medical a good stock to buy?

We do not give buy or sell advice. Strata Critical Medical scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.